Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease.

Cetindag AC, Schipke CG, Esselmann H, Kruse N, Wiltfang J, Schneider A, Fliessbach K, Miklitz C, Maier F, Buerger K, Janowitz D, Ewers M, Stöcklein S, Perneczky R, Rauchmann BS, Kurz C, Teipel S, Kilimann I, Goerss D, Laske C, Sodenkamp S, Najafpour E, Wagner M, Roeske S, Frommann I, Stark M, Brosseron F, Ramirez A, Kleineidam L, Priller J, Spruth EJ, Gemenetzi M, Altenstein S, Düzel E, Glanz W, Incesoy EI, Butryn M, Bauer C, Jessen F, Peters O.

Open source

DOI: 10.1016/j.tjpad.2026.100544
Published: 2026-03-28
Container: J Prev Alzheimers Dis
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.tjpad.2026.100544,
  title = {Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease.},
  author = {Cetindag AC and  Schipke CG and  Esselmann H and  Kruse N and  Wiltfang J and  Schneider A and  Fliessbach K and  Miklitz C and  Maier F and  Buerger K and  Janowitz D and  Ewers M and  Stöcklein S and  Perneczky R and  Rauchmann BS and  Kurz C and  Teipel S and  Kilimann I and  Goerss D and  Laske C and  Sodenkamp S and  Najafpour E and  Wagner M and  Roeske S and  Frommann I and  Stark M and  Brosseron F and  Ramirez A and  Kleineidam L and  Priller J and  Spruth EJ and  Gemenetzi M and  Altenstein S and  Düzel E and  Glanz W and  Incesoy EI and  Butryn M and  Bauer C and  Jessen F and  Peters O.},
  year = {2026},
  journal = {J Prev Alzheimers Dis},
  doi = {10.1016/j.tjpad.2026.100544},
  url = {https://doi.org/10.1016/j.tjpad.2026.100544}
}

RIS

TY  - JOUR
TI  - Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease.
AU  - Cetindag AC
AU  -  Schipke CG
AU  -  Esselmann H
AU  -  Kruse N
AU  -  Wiltfang J
AU  -  Schneider A
AU  -  Fliessbach K
AU  -  Miklitz C
AU  -  Maier F
AU  -  Buerger K
AU  -  Janowitz D
AU  -  Ewers M
AU  -  Stöcklein S
AU  -  Perneczky R
AU  -  Rauchmann BS
AU  -  Kurz C
AU  -  Teipel S
AU  -  Kilimann I
AU  -  Goerss D
AU  -  Laske C
AU  -  Sodenkamp S
AU  -  Najafpour E
AU  -  Wagner M
AU  -  Roeske S
AU  -  Frommann I
AU  -  Stark M
AU  -  Brosseron F
AU  -  Ramirez A
AU  -  Kleineidam L
AU  -  Priller J
AU  -  Spruth EJ
AU  -  Gemenetzi M
AU  -  Altenstein S
AU  -  Düzel E
AU  -  Glanz W
AU  -  Incesoy EI
AU  -  Butryn M
AU  -  Bauer C
AU  -  Jessen F
AU  -  Peters O.
PY  - 2026
JO  - J Prev Alzheimers Dis
DO  - 10.1016/j.tjpad.2026.100544
UR  - https://doi.org/10.1016/j.tjpad.2026.100544
ER  -

APA

AC, C., CG, S., H, E., N, K., J, W., A, S., K, F., C, M., F, M., K, B., D, J., M, E., S, S., R, P., BS, R., C, K., S, T., I, K., D, G., C, L., S, S., E, N., M, W., S, R., I, F., M, S., F, B., A, R., L, K., J, P., EJ, S., M, G., S, A., E, D., W, G., EI, I., M, B., C, B., F, J., & O., P. (2026). Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease.. J Prev Alzheimers Dis. https://doi.org/10.1016/j.tjpad.2026.100544

Source records

europe-pmc · retrieved 2026-09-26T07:55:25.567Z
doaj · retrieved 2026-09-26T07:55:25.562Z